Apellis Pharmaceuticals, Inc. (BIT:1APLS)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
EMPAVELI Revenue	90.67M	98.09M	Log In	Log In	Log In
SYFOVRE Revenue	599.54M	611.86M	Log In	Log In	Log In
Total Product Revenue	690.21M	709.95M	Log In	Log In	Log In
Licensing and Other Revenue	326.18M	71.41M	Log In	Log In	Log In
Revenue (Other)	-1.00K	-	Log In	Log In	Log In
Revenue (Total)	1.02B	781.37M	Log In	Log In	Log In

Updated Sep 30, 2025. Data Source: Fiscal.ai.